Re: Quality-Adjusted Survival with First-Line Cabozantinib or Sunitinib for Advanced Renal Cell Carcinoma in the CABOSUN Randomized Clinical Trial (Alliance)

被引：0
|
作者：
Laguna, Pilar M.
机构：
来源：
JOURNAL OF UROLOGY | 2021年 / 205卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1819 / 1820
页数：3
相关论文
共 50 条
  • [31] Quality-adjusted life-years accrued with cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial
    Strasser, S.
    Abou-Alfa, G.
    Mollon, P.
    Meyer, T.
    Cheng, A.
    El-Khoueiry, A.
    Kelley, R.
    Baron, A.
    Benzaghou, F.
    Valcheva, V.
    Hazra, S.
    Mangeshkar, M.
    Freemantle, N.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 43 - 43
  • [32] Quality-Adjusted Life Years Accrued with Cabozantinib in Patients with Advanced Hepatocellular Carcinoma (AHCC) in the CELESTiAL Trial
    Venerito, Marino
    Abou-Alfa, G. K.
    Mollon, P.
    Meyer, T.
    Cheng, A. -L
    El-Khoueiry, A. B.
    Kelley, R. K.
    Baron, A. D.
    Benzaghou, F.
    Valcheva, V.
    Hazra, S.
    Mangeshkar, M.
    Freemantle, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 61 - 61
  • [33] First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from ASCO 2008
    Wood, L.
    CURRENT ONCOLOGY, 2009, 16 : S26 - S28
  • [34] Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma
    Nagyivanyi, Krisztian
    Budai, Barna
    Biro, Krisztina
    Gyergyay, Fruzsina
    Noszek, Laszlo
    Kueronya, Zsofia
    Nemeth, Hajnalka
    Nagy, Peter
    Geczi, Lajos
    CLINICAL GENITOURINARY CANCER, 2016, 14 (04) : 314 - 322
  • [35] Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
    Barretina-Ginesta, Maria-Pilar
    Monk, Bradley J.
    Han, Sileny
    Pothuri, Bhavana
    Auranen, Annika
    Chase, Dana M.
    Lorusso, Domenica
    Anderson, Charles
    Abadie-Lacourtoisie, Sophie
    Cloven, Noelle
    Braicu, Elena, I
    Amit, Amnon
    Redondo, Andres
    Shah, Ruchit
    Kebede, Nehemiah
    Hawkes, Carol
    Gupta, Divya
    Woodward, Tatia
    O'Malley, David M.
    Gonzalez-Martin, Antonio
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [36] PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
    Flaifel, Abdallah
    Xie, Wanling
    Braun, David A.
    Ficial, Miriam
    Bakouny, Ziad
    Nassar, Amin H.
    Jennings, Rebecca B.
    Escudier, Bernard
    George, Daniel J.
    Motzer, Robert J.
    Morris, Michael J.
    Powles, Thomas
    Wang, Evelyn
    Huang, Ying
    Freeman, Gordon J.
    Choueiri, Toni K.
    Signoretti, Sabina
    CLINICAL CANCER RESEARCH, 2019, 25 (20) : 6080 - 6088
  • [37] Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
    Motzer, Robert J.
    Barrios, Carlos H.
    Kim, Tae Min
    Falcon, Silvia
    Cosgriff, Thomas
    Harker, W. Graydon
    Srimuninnimit, Vichien
    Pittman, Ken
    Sabbatini, Roberto
    Rha, Sun Young
    Flaig, Thomas W.
    Page, Ray
    Bavbek, Sevil
    Beck, J. Thaddeus
    Patel, Poulam
    Cheung, Foon-yiu
    Yadav, Sunil
    Schiff, Edward M.
    Wang, Xufang
    Niolat, Julie
    Sellami, Dalila
    Anak, Oezlem
    Knox, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2766 - +
  • [38] VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
    M Scartozzi
    M Bianconi
    L Faloppi
    C Loretelli
    A Bittoni
    M Del Prete
    R Giampieri
    E Maccaroni
    S Nicoletti
    L Burattini
    D Minardi
    G Muzzonigro
    R Montironi
    S Cascinu
    British Journal of Cancer, 2013, 108 : 1126 - 1132
  • [39] VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
    Scartozzi, M.
    Bianconi, M.
    Faloppi, L.
    Loretelli, C.
    Bittoni, A.
    Del Prete, M.
    Giampieri, R.
    Maccaroni, E.
    Nicoletti, S.
    Burattini, L.
    Minardi, D.
    Muzzonigro, G.
    Montironi, R.
    Cascinu, S.
    BRITISH JOURNAL OF CANCER, 2013, 108 (05) : 1126 - 1132
  • [40] EVERSUN: A PHASE 2 TRIAL OF EVEROLIMUS ALTERNATING WITH SUNITINIB AS FIRST-LINE THERAPY FOR ADVANCED RENAL CELL CARCINOMA (ANZUP TRIAL 0901)
    Davis, I. D.
    Long, A.
    Martin, A.
    Espinoza, D.
    Yip, S.
    Thompson, J. F.
    Kichenadasse, G.
    Harrison, M.
    Lowenthal, R. M.
    Pavlakis, N.
    Azad, A.
    Kannourakis, G.
    Steer, C.
    Goldstein, D.
    Shapiro, J.
    Stockler, M. R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : E68 - E69
12345